Alpha Cognition (ACOG) Expected to Announce Quarterly Earnings on Wednesday

Alpha Cognition (NASDAQ:ACOG) is expected to announce its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Alpha Cognition to post earnings of ($0.33) per share and revenue of $7.04 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

Alpha Cognition (NASDAQ:ACOG) last issued its earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.01). The company had revenue of $6.00 million during the quarter, compared to the consensus estimate of $4.38 million. Alpha Cognition had a negative return on equity of 54.60% and a negative net margin of 153.61%. On average, analysts expect Alpha Cognition to post ($1.38) EPS for the current fiscal year and ($0.61) EPS for the next fiscal year.

Alpha Cognition Stock Up 7.4%

ACOG stock opened at $8.90 on Tuesday. The stock has a 50-day simple moving average of $8.79 and a two-hundred day simple moving average of $7.23. Alpha Cognition has a twelve month low of $4.50 and a twelve month high of $10.14.

Wall Street Analyst Weigh In

ACOG has been the subject of a number of analyst reports. HC Wainwright raised their price objective on shares of Alpha Cognition from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, August 17th. Craig Hallum reiterated a “buy” rating and issued a $17.00 price objective on shares of Alpha Cognition in a research report on Friday, August 14th. Wall Street Zen upgraded Alpha Cognition from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, B. Riley Financial began coverage on Alpha Cognition in a report on Thursday, August 20th. They issued a “buy” rating and a $21.00 price target on the stock. Five research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $18.00.

Insider Activity

In other news, Director Robert Wills acquired 10,000 shares of Alpha Cognition stock in a transaction dated Friday, August 21st. The shares were purchased at an average cost of $9.62 per share, for a total transaction of $96,200.00. Following the transaction, the director owned 32,241 shares of the company’s stock, valued at $310,158.42. This trade represents a 44.96% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 8.60% of the company’s stock.

About Alpha Cognition

Alpha Cognition Inc is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative diseases and cognitive disorders. The company’s work is centered on therapies intended to address the medical needs of patients with Alzheimer’s disease and other conditions affecting cognition.

Its lead commercial product is ZUNOVO (galantamine hydrobromide) extended-release capsules, an orally administered treatment approved by the U.S. Food and Drug Administration for mild-to-moderate dementia of the Alzheimer’s type.